Apple plans to launch AI-powered search tool next year - Bloomberg
Investing.com - Jefferies has raised its price target on Mineralys Therapeutics, Inc. (NASDAQ:MLYS) to $26.00 from $15.00 while maintaining a Hold rating on the stock. The company’s shares have shown remarkable momentum, surging nearly 90% in the past week and over 220% in the last six months.
The price target adjustment follows a significant 80% increase in Mineralys stock price, which exceeded Jefferies’ initial estimate of a 20-25% gain. This surge came after competitor AstraZeneca reported what Jefferies describes as "numerically inferior efficacy for baxdrostat" at a recent ESC presentation. According to InvestingPro data, the stock is now trading near its 52-week high of $30.14, with technical indicators suggesting overbought conditions.
Jefferies noted that while they "still argue efficacy looks similar for docs," the AstraZeneca results represented "a good derisking event" for Mineralys and improved visibility regarding competitive dynamics in the market.
Despite the substantial price target increase, Jefferies maintained its Hold rating on Mineralys stock, stating that the shares "seem reasonably priced" at current levels.
The firm indicated it does not anticipate "major fundamental catalysts" for Mineralys moving forward, except for potential business development activities.
In other recent news, Mineralys Therapeutics reported its second-quarter 2025 earnings, showing a narrower-than-expected loss. The company posted an earnings per share (EPS) of -$0.66, outperforming the forecasted -$1.06. This earnings performance was a positive development for the company. Additionally, Mineralys Therapeutics announced a public offering of $175 million in common stock shares. The offering includes a 30-day option for underwriters to purchase an additional $26.25 million in shares. The proceeds from this offering are intended to support the clinical development of the company’s product candidate, lorundrostat. These developments are part of Mineralys Therapeutics’ ongoing efforts to advance its pipeline and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.